Kevie Feit

588 total citations
13 papers, 459 citations indexed

About

Kevie Feit is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Kevie Feit has authored 13 papers receiving a total of 459 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Kevie Feit's work include Lung Cancer Treatments and Mutations (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Peptidase Inhibition and Analysis (3 papers). Kevie Feit is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Peptidase Inhibition and Analysis (3 papers). Kevie Feit collaborates with scholars based in United States, Japan and United Kingdom. Kevie Feit's co-authors include Robert L. De Jager, Herbert I. Hurwitz, Manuel Modiano, N. Simon Tchekmedyian, Ghassan K. Abou‐Alfa, Eileen M. O’Reilly, Graydon Harker, S. Gail Eckhardt, Richard Létourneau and Luis Báez and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

Kevie Feit

13 papers receiving 445 citations

Peers

Kevie Feit

ONCOL

PRM

EPIDE

J. H. M. Schellens Netherlands

Ronald Drengler United States

Robert L. De Jager United States

L. Hart United States

Enrique Álvarez United States

Eleonora Lai Italy

Serena Lucotti United States

Samira Syed United States

G Mariani Italy

J. H. M. Schellens Netherlands

Kevie Feit

281 ×0.9

ONCOL

156 ×1.0

83 ×0.6

PRM

59 ×0.5

47 ×0.7

EPIDE

Citations per year, relative to Kevie Feit Kevie Feit (= 1×) peers J. H. M. Schellens

Countries citing papers authored by Kevie Feit

Since Specialization

Citations

This map shows the geographic impact of Kevie Feit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevie Feit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevie Feit more than expected).

Fields of papers citing papers by Kevie Feit

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevie Feit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevie Feit. The network helps show where Kevie Feit may publish in the future.

Co-authorship network of co-authors of Kevie Feit

This figure shows the co-authorship network connecting the top 25 collaborators of Kevie Feit. A scholar is included among the top collaborators of Kevie Feit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevie Feit. Kevie Feit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Tibes, Raoul, Mitesh J. Borad, Corina E. Dutcus, et al.. (2018). Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study. British Journal of Cancer. 118(12). 1580–1585. 16 indexed citations

Velcheti, Vamsidhar, Toyoaki Hida, Karen L. Reckamp, et al.. (2017). Phase 2 study of lenvatinib in patients with RET fusion-positive adenocarcinoma of the lung. European Journal of Cancer. 72. S178–S178. 2 indexed citations

Velcheti, Vamsidhar, Toyoaki Hida, Karen L. Reckamp, et al.. (2016). Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung. Annals of Oncology. 27. vi417–vi417. 32 indexed citations

Bono, Johann S. de, L. Rhoda Molife, Guru Sonpavde, et al.. (2011). Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Annals of Oncology. 23(5). 1241–1249. 44 indexed citations

Borad, Mitesh J., Rajesh Ramanathan, Donald W. Northfelt, et al.. (2010). Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 2505–2505. 8 indexed citations

El-Khoueiry, Anthony B., Kevie Feit, H.J. Lenz, et al.. (2008). A phase I study of E7820 in combination with Cetuximab in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 3568–3568. 2 indexed citations

Patel, Shreyaskumar, Mary Louise Keohan, Muhammad Wasif Saif, et al.. (2006). Phase II study of intravenous TZT‐1027 in patients with advanced or metastatic soft‐tissue sarcomas with prior exposure to anthracycline‐based chemotherapy. Cancer. 107(12). 2881–2887. 37 indexed citations

Riely, Gregory J., Shirish M. Gadgeel, Ivan Rothman, et al.. (2006). A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer. 55(2). 181–185. 44 indexed citations

Abou‐Alfa, Ghassan K., Richard Létourneau, Graydon Harker, et al.. (2006). Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer. Journal of Clinical Oncology. 24(27). 4441–4447. 227 indexed citations

10.

Abou‐Alfa, Ghassan K., Eric K. Rowinsky, Yehuda Z. Patt, et al.. (2005). A Phase II Study of Intravenous Exatecan Administered Daily for 5 Days, Every 3 Weeks to Patients With Biliary Tract Cancers. American Journal of Clinical Oncology. 28(4). 334–339. 6 indexed citations

11.

Ajani, Jaffer A., Chris H. Takimoto, Carlos Becerra, et al.. (2005). A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Investigational New Drugs. 23(5). 479–484. 20 indexed citations

12.

Becerra, Carlos, Chris H. Takimoto, Jaffer A. Ajani, et al.. (2004). A phase II study of intravenous DX-8951f administered daily for five days every three weeks to patients with previously untreated metastatic gastric cancer. Journal of Clinical Oncology. 22(14_suppl). 4126–4126. 2 indexed citations

13.

Goldberg, Jonathan S., Matthew I. Milowsky, Lorraine J. Gudas, et al.. (2002). Phase I trial of interferon α2b and liposome‐encapsulated all‐trans retinoic acid in the treatment of patients with advanced renal cell carcinoma. Cancer. 95(6). 1220–1227. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact